MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
MAIA Biotechnology (NYSE American: MAIA) said it completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial for ateganosine in third-line non-small cell lung cancer after resistance to checkpoint inhibitors and chemotherapy. The company enrolled 41 patients in Taiwan, Turkey, Poland, Hungary, Romania and Georgia; U.S. screening continues at three sites. MAIA previously reported median survival of 17.8 months in Parts A/B and Fast Track designation for ateganosine.
How this was made
The 30-second read
Why it matters
Completing international enrollment in Part C is a step toward endpoint reporting, potentially improving sentiment around trial feasibility and timeline, but it does not change efficacy expectations with new data in this release.
Market read
Investors get a concrete execution update (international Part C enrollment complete) that can support positioning ahead of later efficacy maturation, but the release lacks new efficacy prints.
What to watch
Key catalysts are still future: mature disease control rate/OS for Part C and any regulatory interactions tied to Fast Track; trial randomization details may raise expectations that efficacy must confirm.
Background
MAIA’s THIO-101 Phase 2 tests ateganosine (telomere-targeting) followed by cemiplimab (Libtayo) versus ateganosine alone in advanced NSCLC after prior checkpoint inhibitor resistance.
Ticker impact
MAIA says it completed international enrollment in Part C of its Phase 2 THIO-101 ateganosine expansion trial in 3L NSCLC.
Near-term: modest positive bias as investors price progress toward upcoming efficacy readouts; magnitude likely limited without new efficacy data.
The article is a concrete operational milestone (international enrollment complete) but provides no new Part C efficacy results, only previously reported Parts A/B survival context and ongoing U.S. screening.
Market effects
Adds incremental validation for telomere-targeting plus PD-(L)1 sequencing strategies in heavily pre-treated NSCLC.
International site activation across Taiwan, Turkey, Poland, Hungary, Romania, and Georgia supports global trial execution capacity.
Reinforces ongoing competitive activity in 3L NSCLC immunotherapy combinations, though impact is company-specific.
Counterpoint
Operational enrollment milestones may not translate into improved outcomes; without Part C efficacy/OS updates, the market may quickly fade the news.
Key entities
- companyMAIA Biotechnology, Inc.
Clinical-stage biopharmaceutical company developing ateganosine for NSCLC.
- clinical_trialTHIO-101
Phase 2 expansion trial evaluating ateganosine followed by cemiplimab in advanced NSCLC.
- drug_candidateAteganosine
Investigational telomere-targeting/immune-activating therapy in clinical development.
- drugCemiplimab (Libtayo)
PD-(L)1 inhibitor used in the combination arm.
- regulatoryFDA Fast Track designation
Fast Track designation for ateganosine in NSCLC, potentially expediting regulatory review.
